Vasculitis - Pipeline Review, H2 2014

Publisher Name :
Date: 01-Jan-2015
No. of pages: 106
Price : Single User: US $ 2000  US $ 1600 Corporate User: US $ 6000  US $ 4500
Inquire Before Buying
This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Global Markets Direct's, ‘Vasculitis Pipeline Review, H2 2014', provides an overview of the Vasculitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Vasculitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasculitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope


  • The report provides a snapshot of the global therapeutic landscape of Vasculitis

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Vasculitis and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Vasculitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Vasculitis pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products


Reasons to buy


  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Vasculitis

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Vasculitis pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

This report is available at upto 25% Discount till 02 June 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Vasculitis - Pipeline Review, H2 2014

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Vasculitis Overview 8
Therapeutics Development 9
Pipeline Products for Vasculitis - Overview 9
Pipeline Products for Vasculitis - Comparative Analysis 10
Vasculitis - Therapeutics under Development by Companies 11
Vasculitis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Vasculitis - Products under Development by Companies 16
Vasculitis - Companies Involved in Therapeutics Development 17
AnGes MG, Inc. 17
Anthera Pharmaceuticals? Inc. 18
Aprogen, Inc. 19
ChemoCentryx, Inc. 20
Clearside BioMedical, Inc. 21
Epirus Biopharmaceuticals, Inc. 22
F. Hoffmann-La Roche Ltd. 23
GlaxoSmithKline plc 24
Hemostemix Ltd 25
Hospira, Inc. 26
K-Stemcell Co., Ltd. 27
Panacea Biotec Limited 28
Pluristem Therapeutics Inc. 29
Sandoz Inc. 30
XOMA Corporation 31
Vasculitis - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
ACP-01 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
belimumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
beperminogene perplasmid - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
blisibimod - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CCX-168 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
gevokizumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
rituximab biosimilar - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
rituximab biosimilar - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
rituximab biosimilar - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
rituximab biosimilar - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
rituximab biosimilar - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
rituximab biosimilar - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
tocilizumab - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
triamcinolone acetonide - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Vascostem - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Vasculitis - Recent Pipeline Updates 73
Vasculitis - Dormant Projects 99
Vasculitis - Product Development Milestones 100
Featured News & Press Releases 100
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 100
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 100
Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis 101
Jan 10, 2013: Clearside Biomedical Announces Plans For Clinical Testing Of CLS1001 Suprachoroidal Injectable Suspension For Treatment Of Some Eye Diseases 101
Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal 101
Aug 16, 2012: Pluristem Receives Approval From Indian Ministry Of Health For Use Of PLX Cells In Phase II Trial For Treatment Of Buerger's Disease 102
May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress 102
Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis 103
Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology 104
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106

List of Tables

Number of Products under Development for Vasculitis, H2 2014 9
Number of Products under Development for Vasculitis - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Vasculitis - Pipeline by AnGes MG, Inc., H2 2014 17
Vasculitis - Pipeline by Anthera Pharmaceuticals? Inc., H2 2014 18
Vasculitis - Pipeline by Aprogen, Inc., H2 2014 19
Vasculitis - Pipeline by ChemoCentryx, Inc., H2 2014 20
Vasculitis - Pipeline by Clearside BioMedical, Inc., H2 2014 21
Vasculitis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 22
Vasculitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 23
Vasculitis - Pipeline by GlaxoSmithKline plc, H2 2014 24
Vasculitis - Pipeline by Hemostemix Ltd, H2 2014 25
Vasculitis - Pipeline by Hospira, Inc., H2 2014 26
Vasculitis - Pipeline by K-Stemcell Co., Ltd., H2 2014 27
Vasculitis - Pipeline by Panacea Biotec Limited, H2 2014 28
Vasculitis - Pipeline by Pluristem Therapeutics Inc., H2 2014 29
Vasculitis - Pipeline by Sandoz Inc., H2 2014 30
Vasculitis - Pipeline by XOMA Corporation, H2 2014 31
Assessment by Monotherapy Products, H2 2014 32
Number of Products by Stage and Target, H2 2014 34
Number of Products by Stage and Mechanism of Action, H2 2014 36
Number of Products by Stage and Route of Administration, H2 2014 38
Number of Products by Stage and Molecule Type, H2 2014 40
Vasculitis Therapeutics - Recent Pipeline Updates, H2 2014 73
Vasculitis - Dormant Projects, H2 2014 99

List of Figures

Number of Products under Development for Vasculitis, H2 2014 9
Number of Products under Development for Vasculitis - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Products, H2 2014 15
Assessment by Monotherapy Products, H2 2014 32
Number of Products by Top 10 Targets, H2 2014 33
Number of Products by Stage and Top 10 Targets, H2 2014 33
Number of Products by Top 10 Mechanism of Actions, H2 2014 35
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 35
Number of Products by Top 10 Routes of Administration, H2 2014 37
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 37
Number of Products by Top 10 Molecule Types, H2 2014 39
Number of Products by Stage and Top 10 Molecule Types, H2 2014 39

  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Hypereosinophilic Syndrome - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 54
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypereosinophilic Syndrome - Pipeline Review, H1 2017, provides an overview of the Hypereosinophilic Syndrome (Hematological Disorders) pipeline landscape.The hypereosinophilic syndrome (HES) is a disease characterized by a persistently elevated eosinophil count (= 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or......
  • North America Intravenous Immunoglobulin (IVIg) Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 17-May-2017        Price: US 4480 Onwards        Pages: 123
    Intravenous Immunoglobulin, also called gamma globulin or antibodies, is a highly purified blood product preparation that is derived from large pools of plasma donors. Plasma from approximately 1,000 to 10,000 persons is present in each unit or lot of Intravenous Immunoglobulin.Scope of the Report:This report focuses on the Intravenous Immunoglobulin (IVIg) in North America market, especially in United States, Canada and Mexico. This report categorizes the market based on ......
  • Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2017
    Published: 16-May-2017        Price: US 2000 Onwards        Pages: 61
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2017, provides an overview of the Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline landscape.Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, c......
  • Blood Disease Drugs Industry Forecasts - China Focus
    Published: 15-May-2017        Price: US 1800 Onwards        Pages: 145
    This study focuses on China's Blood Disease Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services.......
  • Heparin Markets in China
    Published: 15-May-2017        Price: US 4000 Onwards        Pages: 230
    China's demand for Heparin has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry stru......
  • Heparin Industry Forecasts - China Focus
    Published: 15-May-2017        Price: US 1800 Onwards        Pages: 86
    This study focuses on China's Heparin industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. The Chinese......
  • Blood Disease Drugs Companies in China
    Published: 15-May-2017        Price: US 1800 Onwards        Pages: 89
    This study focuses on China's Blood Disease Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions......
  • Heparin Companies in China
    Published: 15-May-2017        Price: US 1800 Onwards        Pages: 86
    This study focuses on China's Heparin industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods an......
  • Blood Disease Drugs Markets in China
    Published: 15-May-2017        Price: US 4000 Onwards        Pages: 290
    China's demand for Blood Disease Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, i......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs